DAANCE for CHEMOTHERAPY-INDUCED NEUROPATHY

Description

Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.

Conditions

Cancer of the Breast, Chemotherapy-induced Neuropathy

Talk to us

Study Overview

On this page

Study Details

Study overview

Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.

DANCE-BASED AVENUES to ADVANCE NONPHARMACOLOGIC TREATMENT of CHEMOTHERAPY EFFECTS (DAANCE): a MULTICENTER TRIAL

DAANCE for CHEMOTHERAPY-INDUCED NEUROPATHY

Condition
Cancer of the Breast
Intervention / Treatment

-

Contacts and Locations

Columbus

The Ohio State University, Columbus, Ohio, United States, 43220

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Breast Cancer (BC) diagnosis of Stage I-IV including metastatic disease
  • * completed taxane-based chemotherapy for BC at least 3 months ago (no limit on how long ago)
  • * symptomatic for chemotherapy-induced neuropathy (self-report)
  • * postural control score that indicates potential fall-risk
  • * able to understand and comply with directions associated with testing and study treatments
  • * pre-existing vestibular dysfunction
  • * poorly controlled diabetes (hgA1C\>=8)
  • * non-ambulatory (assistive and prosthetic devices allowed)
  • * hearing impairment resulting in less than 10% hearing bilaterally
  • * contraindication to participate in the experimental physical activity per the treating oncologist due to additional condition (e.g., herniated disc, unstable bone metastases)
  • * currently in activity-based therapy (e.g., physical therapy, occupational therapy). May enroll if still meet eligibility criteria once activity-based therapy is complete.

Ages Eligible for Study

40 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ohio State University Comprehensive Cancer Center,

Lise B Worthen-Chaudhari, PhD, MFA, CMES, PRINCIPAL_INVESTIGATOR, Ohio State University

Maryam B Lustberg, MD, MPH, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2025-08-15